During the corresponding time, Lantheus Holdings Inc recorded a revenue increase by 2.69 % year on year, sequentially revenue grew by 2.99 %. While revenue at the Lantheus Holdings Inc 's corporate clients
Lantheus Holdings Inc's Comment on Sales, Marketing and Customers
The company provides products for customers using PET scanners, including PYLARIFY, Neuraceq, MK-6240, LNTH-2501, and NAV-4694. It maintains clinical development partnerships utilizing Neuraceq, MK-6240, and NAV-4694 as research tools. The company manufactures DEFINITY internally while outsourcing the production of other products to third parties. It has acquired Life Molecular Imaging Limited and Evergreen Theragnostics, Inc. The company is developing LNTH-2501 for PET scan applications to stage and localize neuroendocrine tumors in both adult and pediatric patients. It is also pursuing FDA approval for PNT2003 and is involved in related patent litigation. The company focuses on strategic areas such as oncology and neurology and collaborates with strategic partners to expand its pipeline of diagnostic and therapeutic products.
In a significant development for Lantheus Holdings, Inc. (NASDAQ: LNTH), the Portnoy Law Firm has announced a class-action lawsuit on behalf of investors who purchased the company s securities between February 26, 2025, and August 5, 2025. The Los Angeles-based law firm advises investors to file a lead plaintiff motion by the swiftly approaching deadline of November 10, 2025.The class-action suit highlights concerns surrounding Lantheus Holdings financial disclosures and seeks to encapsulate the interests of shareholders affected during the specified Class Period. Such legal challenges often suggest that shareholders might have been misled about the corporate performance or future forecasts during the state...
In a significant stride for the field of nuclear medicine, Lantheus Holdings, Inc., a leading radiopharmaceutical company, has announced the presentation of promising new data at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. Scheduled for June 21-24 in New Orleans, Louisiana, this year s meeting highlights Lantheus s commitment to pioneering advancements in oncology care, particularly in the realm of diagnostic imaging.Lantheus’s presentations will showcase two groundbreaking oncology radiodiagnostic agents poised to enhance clinical practices aimed at improving patient outcomes. As the demand for more precise diagnostic tools continues to grow, Lantheus remain...
Alzheimer s Disease (AD) is a devastating neurodegenerative disorder characterized by the presence of abnormal tau protein tangles in the brain. In a remarkable development for AD research, Lantheus Holdings Inc has announced a collaboration with the National Institute on Aging (NIA) to provide a novel tau imaging agent, MK-6240, for a large consortium clinical trial. This collaboration marks a significant milestone in the quest to better understand and diagnose AD, ultimately leading to the development of effective treatments.The Importance of Tau Imaging in Alzheimer s Disease Research: Tau protein tangles play a crucial role in the pathophysiology of AD, contributing to the cognitive decline and memory l...
Lantheus Holdings Inc’s Comment on Sales, Marketing and Customers
The company provides products for customers using PET scanners, including PYLARIFY, Neuraceq, MK-6240, LNTH-2501, and NAV-4694. It maintains clinical development partnerships utilizing Neuraceq, MK-6240, and NAV-4694 as research tools. The company manufactures DEFINITY internally while outsourcing the production of other products to third parties. It has acquired Life Molecular Imaging Limited and Evergreen Theragnostics, Inc. The company is developing LNTH-2501 for PET scan applications to stage and localize neuroendocrine tumors in both adult and pediatric patients. It is also pursuing FDA approval for PNT2003 and is involved in related patent litigation. The company focuses on strategic areas such as oncology and neurology and collaborates with strategic partners to expand its pipeline of diagnostic and therapeutic products.
Sources:
Lantheus Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lantheus Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Lantheus Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
192.38 %